Teva Pharmaceuticals and Natco Pharma have announced the launch of the first generic versions of Revlimid (lenalidomide) in the U.S., a move that will take a bite out of Bristol Myers Squibb’s (BMS) profit from the blockbuster blood cancer drug.
Source: Drug Industry Daily